Resultado de búsqueda
Hace 1 día · Los resultados generales de seguridad a largo plazo fueron congruentes con el perfil de seguridad conocido del atogepant en migraña crónica y episódica, sin que se identificaran señales de ...
28 de may. de 2024 · AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform. New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ADC.
13 de may. de 2024 · NORTH CHICAGO, Ill. and NEW YORK, May 13, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative ...
Hace 1 día · AbbVie ABBV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Skyrizi ...
20 de may. de 2024 · experienced sites onboarded in 2023, helping diversify AbbVie’s research sites. “Advancing diversity in clinical trials is about more than reaching patients, it’s also about connecting with health care providers as well as caregivers,” says Kim Ribeiro, head of diversity and patient inclusion, AbbVie. “The main way people learn about ...
Hace 4 días · Humira (AbbVie) se mantiene en lo alto del ranking, ocupando el segundo puesto, a pesar de haber perdido la patente. Y aparece Ozempic, la terapia estrella de Novo Nordisk.
Hace 1 día · Abbvie presented positive Phase I and II trial data for three ADC therapies, Teliso-V, ABBV-400 and ABBV-706, in solid tumour patients.
